Abstract:Cardiovascular disease is the leading cause of mortality in many economically developed nations, and its incidence is increasing at a rapid rate in emerging economies. Diet and lifestyle issues are closely associated with a myriad of cardiovascular disease risk factors including abnormal plasma lipids, hypertension, insulin resistance, diabetes and obesity, suggesting that diet-based approaches may be of benefit. Omega-3 longchain-polyunsaturated fatty acids (ω3 LC-PUFA) are increasingly being used in the prevention and management of several cardiovascular risk factors. Both the ω3 and ω6 PUFA families are considered essential, as the human body is itself unable to synthesize them. The conversion of the two precursor fatty acids - linoleic acid (18:2ω6) and α-linoleic acid (α18:3ω3) - of these two pathways to longer (≥C(20)) PUFA is inefficient. Although there is an abundance of ω6 PUFA in the food supply; in many populations the relative intake of ω3 LC-PUFA is low with health authorities advocating increased consumption. Fish oil, rich in eicosapentaenoic (EPA, 20:5ω3) and docosahexaenoic (DHA, 22:6ω3) acids, has been found to cause a modest reduction in blood pressure at a dose level of >3g/d both in untreated and treated hypertensives. Whilst a multitude of mechanisms may contribute to the blood pressure lowering action of ω3 LC-PUFA, improved vascular endothelial cell function appears to play a central role. Recent studies which evaluated the potential benefits of fish oil in type-2 diabetes have helped to alleviate concerns raised in some previous studies which used relatively large dose (5-8 g/d) and reported a worsening of glycemic control. Several meta-analyses have confirmed that the most consistent action of ω3 LC-PUFA in insulin resistance and type-2 diabetes is the reduction in triglycerides. In some studies, fish oil has been found to cause a small rise in LDL-cholesterol, but a change in the LDL particle size, from the smaller more atherogenic form to the larger, less damaging particle size, have also been noted. ω3 LC-PUFA are effective modulators of the inflammation that accompanies several cardio-metabolic abnormalities. Taking into consideration the pleiotropic nature of their actions, it can be concluded that dietary supplementation with ω3 LC-PUFA will lead to improvements in cardio-metabolic health parameters. These fatty acids pose only minor side effects and more importantly, do not interact adversely with the common drug therapies used in the management and treatment of hypertension, dyslipidemia, type-2 diabetes, and obesity/metabolic syndrome, but in some instances work synergistically, thereby providing additional cardiovascular benefits.

Omega-3 polyunsaturated fatty acid biomarkers and risk of type 2 diabetes, cardiovascular disease, cancer, and mortality

Omega-3 Polyunsaturated Fatty Acid Biomarkers and Risk of Type 2 Diabetes, Cardiovascular Disease, Cancer, and Mortality: A Systematic Review and Meta-analysis

Association of Fish and Long-Chain Omega-3 Fatty Acids Intakes with Total and Cause-Specific Mortality: Prospective Analysis of 421 309 Individuals.

n-3 Fatty Acid Biomarkers and Incident Type 2 Diabetes: An Individual Participant-Level Pooling Project of 20 Prospective Cohort Studies

Association of Erythrocyte N-3 Polyunsaturated Fatty Acids with Incident Type 2 Diabetes in a Chinese Population.

Marine N-3 Polyunsaturated Fatty Acids Are Inversely Associated With Risk Of Type 2 Diabetes In Asians: A Systematic Review And Meta-Analysis

Dietary Fats in Relation to Total and Cause-Specific Mortality in a Prospective Cohort of 521 120 Individuals with 16 Years of Follow-Up

Abstract 4142898: Marine N-3 Fatty Acids Improve Carotid Atherosclerosis in Diabetic Patients

Omega-3 Polyunsaturated Fatty Acids and Non-Communicable Diseases: Meta-Analysis Based Systematic Review.

Circulating Omega-3 Polyunsaturated Fatty Acids Levels in Coronary Heart Disease: Pooled Analysis of 36 Observational Studies

Omega-3 fatty acids and incident type 2 diabetes: a systematic review and meta-analysis

Role of ω3 long-chain polyunsaturated fatty acids in reducing cardio-metabolic risk factors

Fish Oil, Plasma n-3 PUFAs, and Risk of Macro- and Microvascular Complications Among Individuals With Type 2 Diabetes

N-3 Polyunsaturated Fatty Acids and Metabolic Syndrome Risk: A Meta-Analysis

Fish, long chain omega-3 polyunsaturated fatty acids consumption, and risk of all-cause mortality: a systematic review and dose-response meta-analysis from 23 independent prospective cohort studies.

Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies.

Changes of urine metabolites in response to n-3 fatty acid supplements and their correlation with metabolic risk factors in patients with type 2 diabetes.

Change Of Plasma Metabolites In Response To Omega-3 Fatty Acids In Chinese Patients With Type 2 Diabetes: A Double-Blinded Randomized Controlled Trial

Effect of ω-3PUFA on Lipids and Expression of Inflammation in Type 2 Diabetes Mellitus

Effect of omega-3 polyunsaturated fatty acids on cardiovascular outcomes in patients with diabetes: A meta-analysis of randomized controlled trials

Fish, Long-Chain N-3 Pufa And Incidence Of Elevated Blood Pressure: A Meta-Analysis Of Prospective Cohort Studies